Epzicom (Abacavir/Lamivudine) for HIV

Overview
Epzicom is a prescription drug approved by the Food and Drug Administration (FDA) to treat HIV-1 infection in combination with other antiretroviral medications. Epzicom is a combination drug composed of Abacavir and Lamivudine, which are also known respectively by the abbreviations ABC and 3TC. Abacavir and Lamivudine are both antiviral medications of the nucleoside reverse transcriptase inhibitor (NRTI) class. Both drugs are believed to work by preventing HIV from replicating in cells.

How do I take it?
Prescribing information states that Epzicom is taken once daily. Epzicom comes in tablet form.

Side effects
The FDA-approved label for Epzicom lists common side effects including insomnia, depression, mood changes, fatigue, malaise, dizziness, vertigo, headache, diarrhea, and sensitivity reactions. Rare but serious side effects listed for Epzicom include severe hypersensitivity reactions, lactic acidosis (a metabolic disorder), hepatomegaly (enlarged liver) with steatosis (fatty degeneration), and severe exacerbation of Hepatitis B.

For more details about this treatment, visit:

Epzicom highlights of prescribing information – ViiV Healthcare

Overview of HIV Treatments – AIDS.gov